• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Herpes zoster subunit vaccine safe and highly effective in adults over 70: The ZOE-70 trial

byJames RoebkerandShaidah Deghan, MSc. MD
September 16, 2016
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The herpes zoster subunit vaccine (HZ/su) demonstrated age-independent efficacy and significantly reduced the incidence of herpes zoster and postherpetic neuralgia (PHN) in adults over age 70.

2. Compared to placebo, the HZ/su vaccine was not associated with an increase in serious adverse events or potential immune-mediated diseases.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Age is the most important risk factor for the development of herpes zoster and subsequent PHN, due to a decline in cell-mediated immunity. A live attenuated vaccine has been the mainstay of primary prevention against herpes zoster. However, the vaccine efficacy declines with age and is contraindicated in immunocompromised patients. The HZ/su vaccine is an experimental subunit vaccine that uses VZV glycoprotein E in combination with an adjuvant (AS01B). The efficacy of this vaccine was evaluated in a randomized controlled trial in adults ³50 years old and demonstrated a significantly reduced risk of herpes zoster. This study evaluated the effectiveness and safety of this vaccine in individuals ³70 years. The results indicated no decline in vaccine efficacy with age or any serious safety concerns. However, the vaccine group had higher rates of injection-site and systemic reactions. If these risks are balanced, the HZ/su vaccine may be of particular benefit to the older patient population with the greatest medical need. Limitations of this study include its mean follow-up time of 3.7 years; more time may be needed to determine the vaccine’s duration of effect.

Click to read the study, published today in NEJM

Relevant Reading: Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults

In-Depth [randomized controlled trial]: This was a randomized, observer-blind, placebo-controlled, multicenter and multinational phase III trial involving a large cohort data from 13,900 (n=10,834, 70-79 years and n=3,066 Âł80) adults Âł70 years old. The primary endpoint was efficacy in reducing the incidence of herpes zoster compared to placebo. Secondary endpoints included the incidence of PHN, safety, and reactogenicity.

RELATED REPORTS

RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

The Moderna mRNA vaccine prevents COVID-19 infection in adolescents

The incidence of herpes zoster per 1000 person-years was 0.9 in the HZ/su group and 0.2 in the placebo group, for an overall vaccine efficacy of 89.8% (95%CI 84.2 to 93.7; p < 0.001). Vaccine efficacy against PHN was 88.8% (95%CI 68.7 to 97.1%; p < 0.001). These results are similar to those in the ZOE-50 trial that evaluated efficacy in adults Âł50. There was also no significant difference in efficacy between adults 71-79 years old and those Âł80.

In the HZ/su and placebo groups, respectively; injection site reactions were reported in 74.1% (8.5% grade 3) and 9.9% (0.2% grade 3), and systemic reactions were reported in 53.0% (6.0% grade 3) and 25.1% (2.0% grade 3). The prevalence of serious adverse events (16.6% of HZ/su recipients and 17.5% of placebo recipients) and potential immune-mediated diseases (1.3% of HZ/su recipients and 1.4% of placebo recipients) were similar between the two groups.

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Shingles (Herpes Zoster)vaccine
Previous Post

Rituximab improves survival in B-cell lineage acute lymphoblastic leukemia

Next Post

No difference in mortality for intensive versus standard reduction in blood pressure in intracerebral hemorrhage: The ATACH-2 trial

RelatedReports

RSV positivity associated with reduced serious bacterial infection risk [Classics Series]
Infectious Disease

RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection

June 24, 2022
Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

June 22, 2022
Waning Tdap vaccine effectiveness among adolescents
Infectious Disease

The Moderna mRNA vaccine prevents COVID-19 infection in adolescents

June 20, 2022
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Plant-based CoVLP+AS03 vaccine protects against COVID-19 infection

June 18, 2022
Next Post
No difference in mortality for intensive versus standard reduction in blood pressure in intracerebral hemorrhage: The ATACH-2 trial

No difference in mortality for intensive versus standard reduction in blood pressure in intracerebral hemorrhage: The ATACH-2 trial

Added tension to transcervical catheters does not expedite delivery

Added tension to transcervical catheters does not expedite delivery

Characteristic differences between young children and adolescents who die by suicide

Characteristic differences between young children and adolescents who die by suicide

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravenous fluid restriction does not improve septic shock outcomes
  • Intravenous vitamin C increases mortality and organ dysfunction in sepsis patients
  • Magnetic resonance based preoperative evaluation for perianal fistulas superior to traditional clinical method and improve surgical outcomes [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.